Blog

Numinus Wellness Provides Corporate Update

Apr 15 • 4 min read

VANCOUVER, BC, April 15, 2024 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, provides an update following unauthorized disclosure in an online newspaper which has come to its attention. As previously announced on January 15,…

The EU’s Plan for a €6.5M Study of Psychedelics To Treat Mental Disorders

Apr 12 • 3 min read

At the recent launch of PsyPal, the first EU-funded clinical research project focused on psychedelic-assisted mental health treatments, MEPs were informed about the innovative strides being made in the field. The project, supported by a €6.5 million grant from Horizon Europe, seeks to explore the therapeutic benefits of psilocybin, particularly for patients in palliative care…

Exploring Psilocybin’s Potential in Diabetes Management

Apr 12 • 3 min read

Diabetes, a chronic condition marked by elevated blood sugar levels, is projected to affect over 700 million people globally by 2045. As the prevalence of diabetes continues to rise, researchers are investigating novel approaches to combat its effects. One such approach involves psilocybin, the primary psychoactive component in hallucinogenic mushrooms, which has recently gained attention…

There’s a New Way To Measure the Potency of Magic Mushrooms

Apr 12 • 3 min read

A collaborative effort among scientists from the University of Texas at Arlington, Scottsdale Research Institute in Phoenix, Shimadzu Scientific Instruments in Maryland, and Millipore-Sigma in Round Rock, Texas, has led to the development of a new method for quantifying the potency of psilocybin and psilocin. These compounds are found in Psilocybe Cubensis, a type of…

Indiana Advances Psilocybin Research with New Funding Initiative

Apr 12 • 3 min read

Governor Eric Holcomb of Indiana has recently enacted a law that earmarks funds for clinical trials to explore the therapeutic effects of psilocybin. This development is part of a broader healthcare legislation that was modified to include provisions on psychedelic research, reflecting a growing interest in the medical potential of such substances. Origins and Goals…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538